Protagonist Reports Third-Quarter 2026 Results; FDA Approves MIMRYLO
Protagonist said MIMRYLO (rusfertide) was approved by the FDA for adults with polycythemia vera, triggering $275 million in payments. The company also plans to initiate a Phase 2b program for PN-881 in early Q1 2027.
MIMRYLO™ (rusfertide) Approved by FDA for the Treatment of Erythrocytosis in Adults with Polycythemia Vera; Approval Triggered $275 Million in Payments to ProtagonistComprehensive Phase 2b Program with PN-881, an Oral IL-17 Antagonist for Psoriasis, Planned to Initiate in Early Q1 2027$300 Million…